European Urology

 

BCG in Superficial Bladder Cancer: A Review of Phase III European Trials

Pagano F. · Bassi P. · Milani C. · Piazza N. · Meneghini A. · Garbeglio A.

Author affiliations

Istituto di Urologia, Università degli Studi, Monoblocco Ospedaliero, Padova, Italy

Related Articles for ""

Eur Urol 1992;21:7–11

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Published online: August 11, 2017
Issue release date: 1992

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-2838 (Print)
eISSN: 1873-7560 (Online)

For additional information: https://www.karger.com/EUR

Abstract

Shortly after Morales’ original report, several phase II trials confirmed the effectiveness of intravesical bacillus Calmette-Guérin (BCG) in superficial bladder cancer therapy. Concerns have been expressed about the toxicity related to this new therapeutic modality. These phase II trial data led European urologists to try to answer some questions related to BCG therapy, such as the optimal schedule and dose, the most effective BCG strain and the value of BCG compared with current chemotherapeutic drugs. To date, phase III trials have shown that BCG is more effective than thiotepa and doxorubicin in reducing tumour recurrences and progression and that BCG seems to be as effective as mitomycin C. Toxicity is significantly higher with BCG compared to chemotherapeutic drugs; no strain of BCG seems to be superior in this respect. Further studies are required to identify the optimal schedule and dose, as well as the best therapeutic efficacy/toxicity ratio.




Related Articles:


Article / Publication Details

Published online: August 11, 2017
Issue release date: 1992

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-2838 (Print)
eISSN: 1873-7560 (Online)

For additional information: https://www.karger.com/EUR


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP